AYTU BioPharma Merges with Rosemont, Surges 44% After Strong Q1 2027 ResultsExplore how Aytu BioPharma’s merger with Rosemont and strong Q1 2027 results boost its specialty‑pharma portfolio and stock momentum.AYTU BIOPHARMA INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 17/11/2026, 22:53 2 minutes to read
Rosemont Acquires Aytu BioPharma, Boosting U.S. Specialty‑Pharma PipelineExplore how Aytu BioPharma’s $2.70/cash takeover by Rosemont boosts shareholder value, expands CNS pipelines, and signals a new era of pharma consolidation.AYTU BIOPHARMA INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 16/11/2026, 22:26 3 minutes to read